The Converse Pharma Group are delighted to announce the completion of negotiations to secure a new 3-year financial agreement with RBSIF.

RBSIF were the banking partner for the group through the MBO process of 2013, and have supported the business through an initial 3-year £37m facility following that transaction.

David Horry, Chairman of the Converse Pharma Group commented :

“The board of the Converse Pharma Group are delighted by the support we received from members of the RBSIF team, both during the MBO process itself, and subsequently throughout the first 3 years of our trading relationship. We are particularly pleased therefore to be in a position to announce the extension of our trading relationship, and are looking forward to an exciting and mutually beneficial future.”